Articles From: GSI Technology, Inc. Board Unanimously Rejects Unsolicited Acquisition Proposal From GigOptix, Inc. to Guangshen Railway Announces 2014 Interim Results


http://media.marketwire.com/attachments/201301/55618_gsitechnologylogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1142560&ProfileId=051205&sourceType=1 SUNNYVALE, CA --
Sign-up for GSI Technology, Inc. Board Unanimously Rejects Unsolicited Acquisition Proposal From GigOptix, Inc. investment picks
http://media.marketwire.com/attachments/201301/55618_gsitechnologylogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1138770&ProfileId=051205&sourceType=1 SUNNYVALE, CA --
Sign-up for GSI Technology, Inc. Receives Unsolicited Acquisition Proposal investment picks
http://media.marketwire.com/attachments/201301/55618_gsitechnologylogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1134778&ProfileId=051205&sourceType=1 SUNNYVALE, CA --
Sign-up for GSI Technology, Inc. Reports First-Quarter Fiscal 2015 Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G018847-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/7/22/11G018847/55618_gsitechnologylogo-819041953321.jpg SUNNYVALE, CA--(Marketwired - July 22, 2014) - GSI Technology, Inc. (NASDAQ: GSIT) will release financial results for its first-quarter fiscal 2015 ended June 30, 2014 at the market close on Thursday, July 31, 2014.
Sign-up for GSI Technology, Inc. to Announce First-Quarter Fiscal 2015 Results on July 31, 2014 investment picks
Company Announcement Trial did not meet the primary endpoint of Progression Free Survival Data to be further analyzed in the coming months COPENHAGEN, Denmark, June 27, 2014 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE:GSK) and Genmab A/S (Copenhagen:GEN) announced today that the Phase III study of ofatumumab (Arzerra(tm)) versus physicians' choice in patients with bulky fludarabine-refractory chronic lymphocytic leukaemia (CLL) did not meet its primary endpoint of progression free survival (PFS). The median PFS, as assessed by the Independent Review Committee, was 5.36 months for ofatumumab and 3.61 months for physicians' choice (Hazard Ratio 0.79, p=0.267). The result reported today is headline data; the full analysis of safety and efficacy data is underway and will be completed in the coming months.
Sign-up for GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians' choice for bulky fludarabine-refractory CLL investment picks
Company Announcement Arzerra approved for use in EU as first-line treatment for CLL in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy Approval based on Phase III data from study with ofatumumab + chlorambucil & Phase II data from study with ofatumumab and bendamustine COPENHAGEN, Denmark, July 3, 2014 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE:GSK) and Genmab A/S (Copenhagen:GEN) announced today that the European Commission (EC) has granted marketing authorization for a new indication for the use of Arzerra (tm) (ofatumumab), a human monoclonal antibody against CD20, in combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy.
Sign-up for GSK and Genmab Receive EU Authorization for Arzerra(tm) (ofatumumab) as First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) in Combination with Chlorambucil or Bendamustine for Patients Ineligible for Fludarabine-based Therapy investment picks
http://media.marketwire.com/attachments/201406/75933_logo1.jpg http://media.marketwire.com/attachments/201404/74550_gsk.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1131553&ProfileId=051205&sourceType=1 LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA --
Sign-up for GSK and Theravance Announce Initiation of Phase III Programme With Fixed Dose Triple Combination Treatment FF/UMEC/VI in Patients With COPD investment picks
2014/9/8
LONDON--U.K. drugmaker GlaxoSmithKline PLC (GSK.LN) Monday publicized positive results from a late-stage study of a treatment for pulmonary arterial hypertension, a condition characterized by constriction of the blood vessels in the lungs.
Sign-up for GSK Announces Results of Late-Stage PAH Trial With Gilead investment picks
- New first-in-class treatment option for this previously treated SAA patient population LONDON , Aug.
Sign-up for GSK receives FDA approval of an additional Promacta® (eltrombopag) indication for use in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST) investment picks
New site is filled with information, patient testimonials, easy-to-use tools and real-world tips for people affected by COPD RESEARCH TRIANGLE PARK, N.C. , Aug.
Sign-up for GSK's COPD.com Relaunch Promotes Understanding and Dialogue about COPD investment picks
2014/7/29
PHILADELPHIA , July 29, 2014 /PRNewswire/ -- GSK (LSE/NYSE: GSK) today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S. Cheryl MacDiarmid , Vice President of GSK's General Medicine business said, "With approximately 21 million adults diagnosed with diabetes in the US 1 , and up to 95 percent of those patients living with type 2 diabetes, we're excited that for the appropriate patients Tanzeum is now available as a treatment option for healthcare professionals." Tanzeum, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a once weekly option for patients, in combination with some other glucose-lowering medicines.
Sign-up for GSK's Tanzeum™ is now available in pharmacies in the U.S. investment picks
WOODSIDE, Calif., June 20, 2014 (GLOBE NEWSWIRE) -- GSV Capital Corp., ("GSV"), (Nasdaq:GSVC) , today announced that William Tanona was appointed GSV's Chief Financial Officer, Treasurer and Secretary and Carl Rizzo was named Chief Compliance Officer, both appointments are effective June 18, 2014.
Sign-up for GSV Capital Corp. Announces Management Transitions investment picks
WOODSIDE, Calif., Aug.
Sign-up for GSV Capital Corp. Reports Second Quarter 2014 Results of Operations investment picks
WOODSIDE, Calif., July 30, 2014 (GLOBE NEWSWIRE) -- GSV Capital Corp., ("GSV"), (Nasdaq:GSVC) , today announced that CEO and Founder Michael T.
Sign-up for GSV Capital Corp. to Present at Needham's Annual Interconnect Conference on August 5, 2014 investment picks
WOODSIDE, Calif., July 25, 2014 (GLOBE NEWSWIRE) -- GSV Capital Corp.
Sign-up for GSV Capital Corp. to Report Second Quarter 2014 Financial Results on Thursday, August 7, 2014 investment picks
NEW YORK (MarketWatch) -- Shares of GT Advanced Technologies (GTAT) slumped 8.7% in premarket trade after they were downgraded to hold from buy by Canaccord Genuity.
Sign-up for GT Advanced Tech slumps in premarket after analyst downgrade investment picks
MERRIMACK, N.H., Aug.
Sign-up for GT Advanced Technologies Inc. Announces Results for Second Quarter Fiscal Year 2014 investment picks
MERRIMACK, N.H., Aug.
Sign-up for GT Advanced Technologies to Participate in Canaccord Genuity Growth Conference investment picks
MERRIMACK, N.H., July 7, 2014 (GLOBE NEWSWIRE) -- GT Advanced Technologies (Nasdaq:GTAT) is presenting at the 2014 Intersolar North America conference being held in San Francisco, California, July 8-10, 2014.
Sign-up for GT Advanced Technologies to Present Its Merlin(TM) Cell Metallization and Interconnect Technology at Intersolar North America Conference July 8, 2014 in San Francisco, California investment picks
MERRIMACK, N.H., June 30, 2014 (GLOBE NEWSWIRE) -- GT Advanced Technologies Inc., (Nasdaq:GTAT) , today announced a realignment of its manufacturing, engineering and supply chain resources to optimize effectiveness across its increasingly diversified business portfolio.
Sign-up for GT Announces Realignment of Manufacturing, Engineering and Supply Chain Resources investment picks
http://media.marketwire.com/attachments/200712/388257_GTDClogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1130115&ProfileId=051205&sourceType=1 ST.
Sign-up for GTDC Appoints Esprinet CEO Alessandro Cattani as Regional Deputy Chairman for Europe investment picks
2014/7/16
By Juro Osawa, Ned Levin and Deborah Ball Italian lottery company GTech SpA is buying International Game Technology, a Las Vegas-based maker of casino equipment, for $4.7 billion in cash and stock, the companies said Wednesday.
Sign-up for GTech agrees to buy casino-equipment maker IGT investment picks
In a bold new direction for the company, Green Technology Solutions, Inc. (OTCBB: GTSO) announced today that it is exploring entry into the fast-growing, multi-billion-dollar cannabis industry in the U.S. GTSO is considering the move because cannabis is one of the top growth industries in the nation.
Sign-up for GTSO Plans Launch into Booming U.S. Cannabis Industry investment picks
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on August 13, 2014, at the 2014 Wedbush Pacgrow Life Sciences Management Access Conference in New York City.
Sign-up for GTx Announces Webcast of Corporate Presentation at the 2014 Wedbush Pacgrow Life Sciences Management Access Conference investment picks
GTx, Inc. (Nasdaq: GTXI) today reported financial results for the quarter and six months ended June 30, 2014.
Sign-up for GTx Provides Corporate Update and Reports Second Quarter 2014 Financial Results investment picks
GTx, Inc. (NASDAQ: GTXI) today announced that the date for its second quarter 2014 financial results press release will be Tuesday, August 5, 2014, prior to the opening of the U.S. stock markets.
Sign-up for GTx, Inc. to Report Second Quarter 2014 Financial Results on August 5, 2014 investment picks
2014/8/21
Records Consolidated Profit Attributable to Equity Holders of RMB329 million HONG KONG , Aug.
Sign-up for Guangshen Railway Announces 2014 Interim Results investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: GSI Technology, Inc. Board Unanimously Rejects Unsolicited Acquisition Proposal From GigOptix, Inc. to Guangshen Railway Announces 2014 Interim Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices